Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

Clinical and Experimental Metastasis

Volumn 26, Issue 8, 2009, Pages 1005-1012

  Urakawa, Hiroshi ^a   Nishida, Yoshihiro ^a   Nakashima, Hiroatsu ^b   Shimoyama, Yoshie ^c   Nakamura, Shigeo ^c   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Extremity; Indoleamine 2,3 dioxygenase; Metastasis; Osteosarcoma; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; INDOLEAMINE 2,3 DIOXYGENASE; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CARCINOGENESIS; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; BONE NEOPLASMS; EXTREMITIES; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS;

EID: 71849101405     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-009-9290-7     Document Type: Article

References (29)

1. G Bacci A Longhi M Versari, et al. 2006 Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy-15-year experience in 789 patients treated at a single institution Cancer 106 5 1154 1161 10.1002/cncr.21724 10.1002/cncr.21724 16421923 (Pubitemid 43297356)
2. SS Bielack B Kempf-Bielack G Delling, et al. 2002 Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 3 776 790 10.1200/JCO.20.3.776 11821461 (Pubitemid 34111386)
3. AL Mellor DH Munn 1999 Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20 10 469 473 10.1016/S0167-5699(99)01520-0 10500295 (Pubitemid 29476077)
4. DH Munn AL Mellor 2007 Indoleamine 2,3-dioxygenase and tumor-induced tolerance J Clin Invest 117 5 1147 1154 10.1172/JCI31178 10.1172/JCI31178 17476344 (Pubitemid 46718399)
5. AJ Muller JB DuHadaway PS Donover, et al. 2005 Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat Med 11 3 312 319 10.1038/nm1196 10.1038/nm1196 15711557 (Pubitemid 40460560)
6. K Ge J Duhadaway D Sakamuro, et al. 2000 Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity Int J Cancer 85 3 376 383 10.1002/(SICI)1097-0215(20000201)85: 3<376::AID-IJC14>3.0.CO;2-1 10652430 (Pubitemid 30030412)
7. K Ge F Minhas J Duhadaway, et al. 2000 Loss of heterozygosity and tumor suppressor activity of BIN1 in prostate carcinoma Int J Cancer 86 2 155 161 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M 10738240 (Pubitemid 30180808)
8. T Tajiri XY Liu PM Thompson, et al. 2003 Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features Clin Cancer Res 9 9 3345 3355 12960121
9. MW Taylor GS Feng 1991 Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism FASEB J 5 11 2516 2522 1907934
10. GP Dunn CM Koebel RD Schreiber 2006 Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 836 848 10.1038/nri1961 10.1038/nri1961 17063185 (Pubitemid 44631652)
11. C Uyttenhove L Pilotte I Theate, et al. 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 10 1269 1274 10.1038/nm934 10.1038/nm934 14502282 (Pubitemid 37279849)
12. V Karanikas M Zamanakou T Kerenid, et al. 2007 Indoleamine 2, 3-dioxygenose (IDO) expression in lung cancer Cancer Biol Ther 6 1258 1262 17700060
13. G Brandacher A Perathoner R Ladurner, et al. 2006 Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clin Cancer Res 12 4 1144 1151 10.1158/1078-0432.CCR- 05-1966 10.1158/1078-0432.CCR-05-1966 16489067 (Pubitemid 43342502)
14. A Witkiewicz TK Williams J Cozzitorto, et al. 2008 Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection J Am Coll Surg 206 5 849 856 10.1016/j.jamcollsurg.2007.12.014 10.1016/j.jamcollsurg.2007.12.014 18471709
15. A Okamoto T Nikaido K Ochiai, et al. 2005 Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells Clin Cancer Res 11 16 6030 6039 10.1158/1078-0432.CCR-04- 2671 10.1158/1078-0432.CCR-04-2671 16115948 (Pubitemid 41170335)
16. K Ino N Yoshida H Kajiyama, et al. 2006 Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer Br J Cancer 95 11 1555 1561 10.1038/sj.bjc.6603477 10.1038/sj.bjc.6603477 17117179 (Pubitemid 44863359)
17. C Liebau AWA Baltzer S Schmidt, et al. 2002 Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma Anticancer Res 22 2A 931 936 12014674
18. MH Cohen J Gootenberg P Keegan, et al. 2007 FDA drug approval summary: Bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 6 713 718 10.1634/theoncologist.12-6-713 10.1634/theoncologist.12-6-713 17602060 (Pubitemid 47036205)
19. E Van Cutsem M Peeters S Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 10.1200/JCO.2006.08.1620 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
20. J Geisse I Caro J Lindholm, et al. 2004 Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies J Am Acad Dermatol 50 5 722 733 10.1016/j.jaad.2003.11.066 10.1016/j.jaad.2003.11.066 15097956 (Pubitemid 38580549)
21. RJ Sylvester APM van der Meijden JA Witjes, et al. 2005 Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 1 86 91 10.1097/01.ju.0000162059.64886. 1c 10.1097/01.ju.0000162059.64886.1c 15947584 (Pubitemid 40825679)
22. DY Hou AJ Muller MD Sharma, et al. 2007 Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res 67 2 792 801 10.1158/0008-5472. CAN-06-2925 10.1158/0008-5472.CAN-06-2925 17234791 (Pubitemid 46192220)
23. P Terness TM Bauer L Rose, et al. 2002 Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites J Exp Med 196 4 447 457 10.1084/jem.20020052 12186837 (Pubitemid 34940984)
24. I Fallarino U Grohmann C Vacca, et al. 2002 T cell apoptosis by tryptophan catabolism Cell Death Differ 9 10 1069 1077 10.1038/sj.cdd.4401073 10.1038/sj.cdd.4401073 12232795
25. F Fallarino U Grohmann S You, et al. 2006 The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells J Immunol 176 11 6752 6761 16709834
26. S Astigiano B Morandi R Costa, et al. 2005 Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer Neoplasia 7 4 390 396 10.1593/neo.04658 10.1593/neo.04658 15967116 (Pubitemid 40664228)
27. DH Munn MD Sharma D Hou, et al. 2004 Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 2 280 290 10.1172/JCI200421583 15254595 (Pubitemid 39071633)
28. R Riesenberg C Weiler O Spring, et al. 2007 Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma Clin Cancer Res 13 6993 7002 10.1158/1078-0432.CCR-07-0942 10.1158/1078-0432.CCR-07-0942 18056175 (Pubitemid 350276880)
29. T Okamoto S Tone H Kanouchi, et al. 2007 Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue Cytotechnology 54 2 107 113 10.1007/s10616-007-9081-4 10.1007/s10616-007-9081-4 19003025 (Pubitemid 47174823)